• Explore /
  • Poster
  • / LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC)

LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC)

Abstract Poster

Authors

null

Anthony B. El-Khoueiry

USC Norris Comprehensive Cancer Center, Los Angeles, CA

Anthony B. El-Khoueiry , Josep M Llovet , Arndt Vogel , David C. Madoff , Richard S. Finn , Sadahisa Ogasawara , Zhenggang Ren , Kalgi Mody , Jerry J. Li , Abby B. Siegel , Leonid Dubrovsky , Masatoshi Kudo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04246177

DOI

10.1200/JCO.2022.40.4_suppl.TPS494

Abstract #

TPS494

Poster Bd #

P1

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Gastrointestinal Cancers Symposium

Effectiveness of transarterial chemoembolization combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma.

Effectiveness of transarterial chemoembolization combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma.

First Author: Fei Cao

First Author: Aiwu Ruth He

First Author: Peter C.C. Fong

First Author: Xiang Nong